Cytosorbents Total Depreciation and Amortization - Cash Flow 2010-2025 | CTSO
Cytosorbents total depreciation and amortization - cash flow from 2010 to 2025. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
| Cytosorbents Annual Total Depreciation and Amortization - Cash Flow (Millions of US $) |
|
|---|---|
| 2024 | $2 |
| 2023 | $2 |
| 2022 | $1 |
| 2021 | $1 |
| 2020 | $1 |
| 2019 | $1 |
| 2018 | $0 |
| 2017 | $0 |
| 2016 | $0 |
| 2015 | $0 |
| 2014 | $0 |
| 2013 | $0 |
| 2012 | $1 |
| 2011 | $1 |
| 2010 | $0 |
| 2009 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.057B | $0.036B |
| CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey. | |||